Provectus Biopharmaceuticals

OverviewSuggest Edit

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. Provectus is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.

TypePublic
Founded2002
HQKnoxville, TN, US
Websiteprovectusbio.com

Latest Updates

Employees (est.) (Dec 2019)2
Revenue (FY, 2015)$0
Share Price (Apr 2021)$0.1
Cybersecurity ratingCMore

Key People/Management at Provectus Biopharmaceuticals

Bruce Horowitz

Bruce Horowitz

Chief Operating Officer, Board Member
Ed Pershing

Ed Pershing

Chairman of the Board
Eric Wachter

Eric Wachter

Chief Technology Officer
Dominic Rodrigues

Dominic Rodrigues

Vice Chairman of the Board
Heather Raines

Heather Raines

Chief Financial Officer
John Lacey

John Lacey

Board Member
Show more

Provectus Biopharmaceuticals Office Locations

Provectus Biopharmaceuticals has offices in Knoxville and Brentwood
Knoxville, TN, US (HQ)
10025 Investment Dr #250Knoxville
Show all (2)

Provectus Biopharmaceuticals Financials and Metrics

Provectus Biopharmaceuticals Revenue

USD

Net income (FY, 2020)

(6.7m)

EBIT (FY, 2020)

(5.0m)

Market capitalization (19-Apr-2021)

26.7m

Closing stock price (19-Apr-2021)

0.1

Cash (31-Dec-2020)

97.2k

EV

52.9m
Provectus Biopharmaceuticals's current market capitalization is $26.7 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

8.7m8.8m11.0m13.3m16.0m5.5m3.3m2.3m2.2m

R&D expense

5.0m3.6m5.1m10.7m8.5m8.2m4.7m4.0m2.8m

Operating expense total

13.7m12.4m16.1m24.0m24.5m13.7m8.1m6.3m5.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

General and administrative expense

3.2m3.9m2.5m2.3m2.3m2.2m3.1m3.0m2.3m2.2m2.4m2.9m6.1m3.0m3.3m2.5m924.1k728.9k962.7k1.3m829.4k759.3k631.1k438.4k538.8k514.4k

R&D expense

2.0m3.4m1.7m740.5k778.3k1.3m1.2m1.0m1.4m2.3m2.1m2.7m2.4m2.0m2.5m1.9m2.4m2.4m1.9m987.2k528.4k1.0m1.2m1.0m909.4k696.5k

Operating expense total

5.2m7.3m4.1m3.1m3.1m3.5m4.2m4.0m3.7m4.5m4.4m5.6m8.5m5.0m5.8m4.4m3.3m3.1m2.9m2.3m1.4m1.8m1.8m1.4m1.4m1.2m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.2m15.7m17.4m14.2m1.2m105.5k51.0k590.7k97.2k

Accounts Receivable

8.9m55.1k3.9k

Prepaid Expenses

978.0k41.2k400.4k370.2k350.2k322.5k

Current Assets

19.1m14.7m1.8m958.3k1.0m996.0k423.7k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

14.4m10.8m4.9m4.1m1.8m4.3m4.6m8.3m16.6m18.1m17.8m14.2m23.1m18.9m9.8m4.9m5.2m437.0k1.1m208.3k244.1k130.6k231.9k1.8m1.3m434.8k213.7k1.5m

Accounts Receivable

74.2k3.8k

Prepaid Expenses

53.8k140.8k93.0k45.3k1.2m1.2m1.1m336.9k316.6k187.2k250.5k245.0k325.4k300.7k273.6k207.8k272.0k242.4k169.1k240.4k142.7k

Current Assets

14.5m10.9m5.0m4.1m1.9m4.5m4.7m8.3m16.6m18.1m17.8m15.9m24.5m19.9m10.4m5.4m5.4m887.5k1.5m533.7k744.8k1.4m441.7k2.7m1.9m894.0k528.3k1.6m
USDQ2, 2011

Debt/Equity

0.4 x

Debt/Assets

0.3 x

Financial Leverage

1.4 x
Show all financial metrics

Provectus Biopharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

Provectus Biopharmaceuticals Online and Social Media Presence

Embed Graph

Provectus Biopharmaceuticals News and Updates

Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions

KNOXVILLE, TN, March 31, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Melanoma Research had published results from an investigator-led, single-center study of Australian in-transit melanoma (ITM) patients who received intralesional (aka intratumoral) PV-10 under a Provectu…

Provectus Biopharmaceuticals Receives Notice of Allowance for Adult Solid Tumor Cancer Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office

KNOXVILLE, TN, March 30, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/678,133, which covers the use of intralesional (aka intratumoral) PV-10, an injectable formulation of Prov…

Provectus Biopharmaceuticals Receives Notice of Allowance for Refractory Pediatric Solid Tumor Cancer Monotherapy and Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office

KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872, which covers the use of intralesional (aka intratumoral) PV-10, an injectable formulation of Provectus’…

Provectus Biopharmaceuticals Announces Release of Preprint Manuscript Describing Preclinical Study of PV-10® Immunotherapy and Chemotherapy for Treatment of Pancreatic Cancer

KNOXVILLE, TN, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) has released a manuscript preprint describing how investigational autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus’ proprietary small mol…

Provectus Biopharmaceuticals Announces Oral Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Checkpoint-Refractory Advanced Cutaneous Melanoma at Melanoma Bridge 2020

KNOXVILLE, TN, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated preliminary patient response, safety, and immune correlative data, as well as new preliminary PV-10-treated lesion response data, from the Company's ongoing Phase 1b/2 study of autolytic cancer im…

Provectus Biopharmaceuticals Announces Presentation of PV-10® Pancreatic Cancer Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) presented non-clinical data from ongoing research on investigational autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus' proprietary small …
Show more

Provectus Biopharmaceuticals Frequently Asked Questions

  • When was Provectus Biopharmaceuticals founded?

    Provectus Biopharmaceuticals was founded in 2002.

  • Who are Provectus Biopharmaceuticals key executives?

    Provectus Biopharmaceuticals's key executives are Bruce Horowitz, Ed Pershing and Eric Wachter.

  • How many employees does Provectus Biopharmaceuticals have?

    Provectus Biopharmaceuticals has 2 employees.

  • Who are Provectus Biopharmaceuticals competitors?

    Competitors of Provectus Biopharmaceuticals include Eczema Honey, TOT BIOPHARM and Celltrion Healthcare.

  • Where is Provectus Biopharmaceuticals headquarters?

    Provectus Biopharmaceuticals headquarters is located at 10025 Investment Dr #250Knoxville, Knoxville.

  • Where are Provectus Biopharmaceuticals offices?

    Provectus Biopharmaceuticals has offices in Knoxville and Brentwood.

  • How many offices does Provectus Biopharmaceuticals have?

    Provectus Biopharmaceuticals has 2 offices.